Bicara Therapeutics’ (BCAX) “Outperform” Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a report published on Friday morning,RTT News reports. They currently have a $30.00 price objective on the stock. Several other equities analysts have also recently issued reports on the company. HC Wainwright decreased their price objective on Bicara Therapeutics from […]
Wedbush reiterated their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a report published on Friday morning,RTT News reports. They currently have a $30.00 price objective on the stock. Several other equities analysts have also recently issued reports on the company. HC Wainwright decreased their price objective on Bicara Therapeutics from […]
